Related Experiment Video
Updated: Jan 17, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Reviving p18INK4c: Harnessing a tumor suppressor for cancer treatment
Dominika Jerka1, Klaudia Bonowicz-Kozłowska2, Yidong Bai3
1Department of Histology and Embryology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, 85-092, Poland.
Abstract:
Cancer is marked by unchecked cell growth and proliferation, typically resulting from disruptions in the cell cycle. Central to this process are cyclins and cyclin-dependent kinases (CDKs), which regulate cell division. Overactivation of CDK-cyclin complexes is commonly observed in cancer, leading to the development of CDK inhibitors (CDKIs) as therapeutic agents. Among these, p18INK4c, a key member of the INK4 family, a group of cyclin-dependent kinase inhibitors that regulate cell cycle progression by inhibiting CDK4/6 activity, plays a critical role in maintaining cell cycle homeostasis. By inhibiting CDK4 and CDK6, p18INK4c prevents phosphorylation of the retinoblastoma protein (Rb), inducing cell cycle arrest and inhibiting cancer cell proliferation. Dysregulation of p18INK4c expression is observed across several cancers, strongly supporting its role as a tumor suppressor. This review explores the therapeutic potential of restoring p18INK4c function in cancer treatment. We analyze the molecular mechanisms by which p18INK4c regulates the cell cycle and how its dysregulation promotes cancer progression. Additionally, we highlight potential strategies aimed at enhancing p18INK4c activity, underscoring its promise as a target for reactivating tumor-suppressive pathways in cancer therapy.
Insights
Restoring p18INK4c function shows therapeutic potential for cancer treatment by reactivating tumor-suppressive pathways. This cyclin-dependent kinase inhibitor halts cancer cell proliferation by regulating cell cycle progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Cancer is characterized by uncontrolled cell growth due to cell cycle disruptions.
- Cyclins and cyclin-dependent kinases (CDKs) are key regulators of cell division, and their overactivation is common in cancer.
- CDK inhibitors (CDKIs) are therapeutic agents targeting these pathways.
Purpose of the Study:
- To explore the therapeutic potential of restoring p18INK4c function in cancer treatment.
- To analyze the molecular mechanisms of p18INK4c in cell cycle regulation and cancer progression.
- To highlight strategies for enhancing p18INK4c activity.
Main Methods:
- Review of literature on p18INK4c function in cell cycle regulation.
- Analysis of molecular mechanisms underlying p18INK4c's tumor-suppressive role.
- Identification of therapeutic strategies targeting p18INK4c.
Main Results:
- p18INK4c, an INK4 family member, inhibits CDK4/6 activity, preventing retinoblastoma protein (Rb) phosphorylation.
- This inhibition induces cell cycle arrest and suppresses cancer cell proliferation.
- Dysregulation of p18INK4c is observed in various cancers, confirming its tumor suppressor role.
Conclusions:
- Restoring p18INK4c function presents a promising therapeutic strategy for cancer.
- Targeting p18INK4c can reactivate tumor-suppressive pathways.
- Further research into enhancing p18INK4c activity is warranted for cancer therapy development.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
02:34Inhibition of Cdk Activity
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...